Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

Investigation Alert PYPL, FLGT, OLO, KSS: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?

9:02 am ET December 8, 2022 (Globe Newswire) Print
Investigation Alert PYPL, FLGT, OLO, KSS: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?GlobeNewswireDecember 08, 2022

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) --

PayPal Holdings, Inc. (NASDAQ: PYPL)

Johnson Fistel, LLP is investigating potential claims on behalf of PayPal Holdings, Inc. (NASDAQ: PYPL) ("PayPal" or the "Company") against certain of its officers and directors.

If you are a current, long-term shareholder of PayPal holding shares beforeFebruary 3, 2021, you can click or copy and paste the link below in a browser to join this action:

https://www.johnsonfistel.com/investigations/paypal-holdings-inc-pypl

Recently a class action complaint was filed against PayPal. The class action lawsuit alleges that PayPal throughout the Class Period touted the growth in its Net New Active Accounts ("NNAs") and instructed investors to value the high growth in this metric as one of the most important indicators of how PayPal was performing. But as the PayPal class action lawsuit alleges, while touting its NNA growth, PayPal failed to disclose that many of the additional users acquired through its cash account creation incentive campaigns were illusory because those incentive campaigns were easily susceptible to fraud. Specifically, PayPal failed to disclose that its cash incentive campaigns significantly increased PayPal's susceptibility to bot farms that were able to systematically take advantage of PayPal's $10.00 account opening by creating millions of illegitimate accounts, which ultimately generated no future revenue for PayPal. In addition, the PayPal class action lawsuit alleges that investors were unaware of the lengths PayPal was going to keep inactive customers and fake bot accounts on the platform to prevent churn and inflate its NNA guidance which would have provided a more realistic view of the true demand for PayPal's platform.

Fulgent Genetics, Inc. (NASDAQ: FLGT)

Johnson Fistel, LLP is investigating potential claims on behalf of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT) against certain of its officers and directors.

If you have continuously owned Fulgent shares since March 22, 2019, you can click or copy and paste the link below in a browser to join this action:

https://www.johnsonfistel.com/investigations/fulgent-genetics-inc-flgt

Recently a class action complaint was filed against Fulgent. The complaint alleges that the defendants made false statements and/or concealed that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent's revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Olo Inc. (NYSE: OLO)

Johnson Fistel, LLP is investigating potential claims on behalf of Olo Inc. ("Olo" or the "Company") (NYSE: OLO) against certain of its officers and directors.

If you have continuously owned Olo shares before August 11, 2021, you can click or copy and paste the link below in a browser to join this action:

https://www.johnsonfistel.com/investigations/olo-class-action

Recently a class action complaint was filed against Olo. Plaintiff alleges that Defendants made materially false and misleading statements throughout the Class Period. Specifically, Plaintiff alleges that Defendants failed to disclose that: (1) Subway was ending its contract with Olo; and (2) Olo's key business metric - active locations - could not continue to grow as Defendants touted due to the loss of Subway's business.

Kohl's Corporation (NYSE: KSS)

Johnson Fistel, LLP is investigating potential claims on behalf of Kohl's Corporation ("Kohl's" or the "Company") (NYSE: KSS) against certain of its officers and directors.

If you have continuously owned Kohl's shares before October 20, 2020, you can click or copy and paste the link below in a browser to join this action:

https://www.johnsonfistel.com/investigations/kohls-corporation

Recently a class action complaint was filed against Kohl's. Plaintiff alleges that Defendants made materially false and misleading statements throughout the Class Period. Specifically, Plaintiff alleges that Defendants failed to disclose, inter alia, that: (i) Kohl's Strategic Plan was not well tailored to achieving the Company's stated goals; (ii) Defendants overstated the Company's success in executing its Strategic Plan; and (iii) Kohl's had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP

Jim Baker, Lead Securities Analyst

Telephone: (619) 814-4471

Email: jimb@johnsonfistel.com



Primary Logo

comtex tracking

COMTEX_420424070/2010/2022-12-08T09:02:25

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.